JP Morgan 2024 – Xavier Duportet

There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome. But doing gene therapy on the microorganisms that make up the microbiome? That’s a bit more novel.

At the event last month, editor-in-chief Jonah Comstock touched base with Xavier Duportet, CEO at Eligo Bioscience, a French company working on that very thing. His company uses CRISPR gene editing to turn microorganisms into “local drug factories” to treat a variety of conditions in the body, starting with moderate to severe acne.

While they’re starting with a topical cream targeting the skin microbiome, future applications are geared toward the gut microbiome, and even the tumour microbiome.

Tune in to the video below to hear Duportet explain the company’s vision and future plans, the value of the conference for his company, and some broader trends in gene therapy and pharma innovation.